• PDF / 169,321 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 62 Downloads / 167 Views

DOWNLOAD

REPORT

---

1 S

Nausea, vomiting and off-label use: case report In a retrospective study of 11 patients, one patient [age and sex not stated] was described, who developed nausea and vomiting during treatment with bortezomib, dexamethasone and off-label use of venetoclax for relapsed refractory multiple myeloma (RRMM). The patient, who was diagnosed with RRMM, was scheduled to receive Ven-VD regimen comprising oral venetoclax 800mg daily (as a part of a preapproval access program; off-label use), bortezomib 1.3 mg/m2 on days 1, 4, 8, 11 and oral dexamethasone 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 [not all routes stated]. Eventually, the patient developed grade 3 nausea and vomiting [duration of treatments to reactions onset not stated]. Venetoclax, bortezomib and dexamethasone was discontinued [outcomes not stated]. Jelinek T, et al. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort. Hematological 803504258 Oncology 38: 412-414, No. 3, Aug 2020. Available from: URL: http://doi.org/10.1002/hon.2736

0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 3 Oct 2020 No. 1824